Skip to main navigation Utility PATIENTS CAREERS CONTACT US ABOUT OUR SCIENCE PIPELINE & PROGRAMS HEARING LOSS INVESTORS & MEDIA Investor FAQ Where is Frequency’s corporate headquarters located? Where is the company incorporated? When did Frequency go public? What is Frequency’s fiscal year-end? How is Frequency’s stock traded? Who is Frequency's transfer agent and whom do I contact with questions about my shares? How can I purchase shares? Who is Frequency’s legal counsel and independent auditor? Where can I get the latest corporate news releases? How can I view documents Frequency has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q? Whom should I contact if I have future questions? Interested in joining our team? Explore careers © 2021 Frequency Therapeutics Open Positions Contact Privacy Policy Terms and conditions

Skip to main navigation Utility PATIENTS CAREERS CONTACT US ABOUT OUR SCIENCE PIPELINE & PROGRAMS HEARING LOSS INVESTORS & MEDIA Investor Relations Corporate Profile Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore function – first in hearing loss and then in multiple sclerosis (MS) – by developing therapeutics that activate a person’s innate regenerative potential within the body through the activation of progenitor cells. Frequency’s hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for sensorineural hearing loss. Frequency is also following early restorative signals in MS to develop medicines with the same underlying regenerative science being brought to hearing loss. Corporate Presentation Corporate Presentation - November 2021 Annual Report and Proxy Statement 2020 Annual Report 2021 Proxy Statement Stock Quote Nov 27, 2021 5:44 PM EST Change Today's Open Today's High Volume Previous Close Today's Low Stock VIEW MORE STOCK INFORMATION Recent News NOV 15 Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results NOV 9 Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis OCT 27 Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program News VIEW MORE NEWS Data Provided by Refinitiv. Minimum 15 minutes delayed. Interested in joining our team? Explore careers © 2021 Frequency Therapeutics Open Positions Contact Privacy Policy Terms and conditions